Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products > Therapeutic Antibodies

Socazolimab Biosimilar(Anti-B7-H1 / PD-L1 / CD274 Reference Antibody)

  Cat. No.:  A1029   Featured
Chemical Structure
2305043-30-3
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma.
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.: 2305043-30-3
pH value: Corresponds to reference standard: PASS
Non-reduced CE-SDS: >95%
SEC-HPLC: >95%
Isoelectric Point: Corresponds to reference standard
Osmolality: Corresponds to reference standard: PASS
Peptide mapping: Corresponds to reference standard: PASS
N-terminal sequence: Corresponds to reference standard: PASS
MSDS
Cat. No. Product name Field of application
A1061 Osemitamab Biosimilar(Anti-CLDN18.2 Reference Antibody) Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study.
A1060 Muromonab Biosimilar（Anti-CD3 Reference Antibody） Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection.
A1059 Atoltivimab Biosimilar（Anti-EBOV Reference Antibody） Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection.
A1058 Navivumab Biosimilar（Anti-HA Reference Antibody） Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2.
A1057 Anti-IAV Reference Antibody Biosimilar
A1056 Odesivimab Biosimilar（Anti-Zaire Ebola virus Reference Antibody） Odesivimab is a human monoclonal antibody, targeting Ebola virus glycoprotein with a KD value of 7.74 nM for recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain protein. Odesivimab can be used in research of Ebola virus infection.
A1055 Cosfroviximab Biosimilar（Anti-Zaire Ebola virus Reference Antibody） Cosfroviximab (c13C6-FR1) is a mouse/human chimeric monoclonal antibody against Ebola virus glycoprotein (EBOV-GP).
A1054 Porgaviximab Biosimilar（Anti-Zaire Ebola virus Reference Antibody） Porgaviximab is a monoclonal antibody that can be used Ebola infection research.
A1053 Larcaviximab Biosimilar（Anti-Zaire Ebola virus Reference Antibody） Larcaviximab (c4G7-N) is an IgG1 kappa anti-Ebola virus glycoprotein chimeric monoclonal antibody.
A1052 Romlusevimab Biosimilar（Anti-Spike RBD Reference Antibody） Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia